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Transfusion-related acute lung injury (TRALI) 
is defined as new onset or worsening of pulmo-
nary function with acute hypoxemia and non-
cardiogenic pulmonary edema during or within 6 h   
after blood transfusion (Kopko, 2004; Chapman   
et al., 2009; Silliman et al., 2009; Vlaar et al., 
2009). Associated clinical features include dys-
pnea, tachypnea, cyanosis, tachycardia, and froth   
in  an  endotracheal  tube  (Kopko,  2004; Toy   
et al., 2005; Silliman et al., 2009). Although rare 
(1 case per 2,000–5,000 transfusions of blood 
or blood products, with a mortality rate of 6%; 
Kopko, 2004; Toy et al., 2005; Silliman et al., 
2009; Vlaar et al., 2009), the incidence of TRALI 
is increasing as clinical awareness increases and 
a more uniform case definition is being used. 
As a result, TRALI is now the leading cause of 
transfusion-related mortality in developed coun-
tries (Kopko, 2004; Toy et al., 2005; Silliman   
et al., 2009; Vlaar et al., 2009).
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Transfusion-related acute lung injury (TRALI), a form of noncardiogenic pulmonary edema 
that develops during or within 6 h after a blood transfusion, is the most frequent cause of 
transfusion-associated death in the United States. Because development of TRALI is associ-
ated with donor antibodies (Abs) reactive with recipient major histocompatibility complex 
(MHC), a mouse model has been studied in which TRALI-like disease is caused by injecting 
mice with anti–MHC class I monoclonal Ab (mAb). Previous publications with this model 
have concluded that disease is caused by FcR-dependent activation of neutrophils and 
platelets, with production of reactive oxygen species that damage pulmonary vascular 
endothelium. In this study, we confirm the role of reactive oxygen species in the patho-
genesis of this mouse model of TRALI and show ultrastructural evidence of pulmonary vascular 
injury within 5 min of anti–MHC class I mAb injection. However, we demonstrate that 
disease induction in this model involves macrophages rather than neutrophils or platelets, 
activation of complement and production of C5a rather than activation of FcRI, FcRIII, 
or FcRIV, and binding of anti–MHC class I mAb to non-BM–derived cells such as pulmo-
nary vascular endothelium. These observations have important implications for the preven-
tion and treatment of TRALI.
© 2011 Strait et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Un-
ported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Figure 1.  mTRALI resembles human TRALI. (A) BALB/c male mice (four mice per group) were injected i.v. with 34-1-2s (mouse IgG2a anti–H-2Dd/Kd 
mAb) or mouse IgG2a isotype control mAb (IA6.2) and evaluated for the next 26 min for changes in breathing pattern suggestive of dyspnea (shown as 
increases in Penh). Data are representative of more than five experiments. (B) BALB/c (H-2d), B10.D2 (H-2d), BALB/k (H-2k), and C57BL/6 (H-2b) background 
male mice (four mice per group) were injected i.v. with 34-1-2s. Penh was evaluated. Pooled graph is representative of two BALB/k, three C57B/6, three 
B10.D2, and three BALB/c experiments. (C) BALB/c male mice (10 mice per group) were injected i.v. with 34-1-2s or control mAb. Arterial blood pO2 was 
measured 15 min later. Results are pooled from two experiments. (D) BALB/c male mice (five mice per group) were injected i.v. with 34-1-2s or control 
mAb; 30 min later, lungs were harvested, and percent water content was measured. Data are representative of three experiments. (E) BALB/c male mice 
(five mice per group) were injected i.v. with 34-1-2s or control mAb; 30 min later, BAL fluid was collected, and its protein content was measured. Data are 
representative of two experiments. (F) Representative H&E-stained sections of lung from BALB/c male mice injected i.v. with control mAb (1 and 2) or  
34-1-2s (3–6). Lungs were harvested 0.5 (3 and 4) or 24 h (1, 2, 5, and 6) later. Arrows are pointing to neutrophils. (G) BALB/c male mice (five mice per JEM Vol. 208, No. 12 
Article
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IgG2a anti–H-2d mAbs fail to induce detectable disease. 
These features raised doubts about the pathogenic mecha-
nism that was reported and led us to perform additional 
experiments that injected mice of the same strain (BALB/c) 
with the same anti–MHC class I mAb. Based on the results   
of these experiments, we now report that the TRALI-like 
syndrome  induced  by  this  mAb  is  mediated  primarily  by 
complement, particularly C5a, rather than by FcR, and by 
peripheral blood monocytes, rather than platelets or neutro-
phils. We also find that anti–MHC class I mAb must react 
with non-BM–derived cells, such as vascular endothelial cells, 
to cause disease. In addition, we demonstrate direct ultrastruc-
tural damage to pulmonary vascular endothelium by 5 min 
after mAb injection, confirm the importance of ROIs in dis-
ease pathogenesis, provide an explanation for the susceptibil-
ity of male but not female mice, show that prestimulation of 
the inhibitory FcR, FcRIIb, suppresses TRALI, and demon-
strate that anti–H-2d mAbs that are individually incapable of 
inducing TRALI-like disease can provoke this disorder when 
injected together. In addition to providing information that 
may be important for TRALI prevention or treatment, these 
results identify potential artifacts that can confuse investigations 
of the pathogenesis of other immune-mediated disorders.
RESULTS
Anti–H-2d mAb rapidly disrupts pulmonary  
vascular basement membranes to induce TRALI-like  
disease in H-2d mice
Injection of BALB/c and other H-2d haplotype mice with 
34-1-2s, a mouse IgG2a mAb which binds to H-2Dd and 
H-2Kd (Ozato et al., 1982), caused an H-2d–specific change 
in breathing pattern (Fig. 1, A and B) shown by barometric 
plethysmography as increased “enhanced pause” (Penh), which 
reflects a selective increase in the duration of the late phase of 
expiration (Hamelmann et al., 1997). This was accompanied 
by decreased blood oxygenation (pO2; Fig. 1 C), increased 
lung water content (Fig. 1 D), leakage of protein into the air-
ways (Fig. 1, E and F), and temporary redistribution of blood 
neutrophils to the lungs (Fig. 1, F and G). Changes in breath-
ing pattern were observed by 2 min after mAb injection (Fig. 1, 
A and B) and correlated closely with increases in lung water 
(Fig. 1 H) and development of shock and hemoconcentration 
(not depicted). Physical disruption of the capillary walls, charac-
terized by separation of endothelial cells from the underlying 
Laboratory features associated with TRALI can include 
transient acute leukopenia (Kopko and Popovsky, 2004), 
antibodies (Abs) in donor plasma that react with recipient 
HLA class I or II, granulocytes or monocytes (Kopko et al., 
2003; Gajic et al., 2007; Chapman et al., 2009; Silliman et al., 
2009), and increased donor plasma concentration of sub-
stances, such as lipid mediators, that can activate recipient 
neutrophils (Silliman et al., 1997, 1998; Gajic et al., 2007; 
Fung and Silliman, 2009). These laboratory features suggest 
two principle etiologies of TRALI that might act together or 
independently: (1) Ab activation of leukocytes that damages 
recipient lungs (Kopko et al., 2003; Silliman et al., 2009; 
Shaz et al., 2011) and (2) increased concentrations of platelet-
derived vasoactive mediators that develop during blood stor-
age and directly increase pulmonary vascular permeability or 
induce leukocytes to release mediators that have this effect 
(Silliman et al., 2009; Shaz et al., 2011). Although TRALI 
has occurred in individuals who appeared to have no predis-
posing risk factor before transfusion (Engelfriet et al., 2001; 
Toy et al., 2005), it occurs most commonly in individuals 
who have disorders, such as septic shock, recent surgery, or 
disseminated intravascular coagulation that may act additively 
or synergistically with Abs or mediators delivered by trans-
fusion to acutely increase pulmonary vascular permeability 
(Gajic et al., 2007; Chapman et al., 2009; Fung and Silliman, 
2009; Silliman et al., 2009; Vlaar et al., 2009; Shaz et al., 
2011). Such preexisting disorders may prime leukocytes or vas-
cular endothelial cells to react more potently to antileukocyte 
Abs and/or mediators.
Previously reported studies have modeled human Ab–
induced TRALI by injecting mice of the H-2d haplotype 
with 34-1-2s, a mouse IgG2a mAb to H-2Dd and H-2Kd 
(MHC class I antigens; Looney et al., 2006, 2009). Injection 
of this mAb rapidly induces pulmonary vascular leak that in-
creases lung water content and is associated with temporary 
neutropenia (Looney et al., 2006). Studies with this system 
suggested a pathogenic mechanism that involves FcRs, neu-
trophils, and platelets, with generation of reactive oxygen   
intermediates (ROIs) that cause pulmonary vascular leak by 
damaging vascular endothelium (Looney et al., 2006, 2009). 
However, these studies did not address two important fea-
tures of this model: (1) 34-1-2s induces TRALI-like disease 
in normal male but not female mice, although human TRALI 
occurs with equal frequency in both genders, and (2) other 
group) were injected i.v. with 34-1-2s. Blood was drawn before or 30 or 240 min after challenge, and absolute neutrophil count (ANC) was measured. 
Data are representative of three experiments. (H) BALB/c male mice (10 mice per group) were injected i.v. with 34-1-2s or control mAb. Maximum Penh 
during the subsequent 26 min was determined. Lungs were harvested 30 min after injection and evaluated for percent water content. r2 for percent water 
weight of lungs versus maximum Penh = 0.521. Data are representative of two experiments. (I) Representative electron micrographs of lungs harvested 
from BALB/c male mice before or 5 min after i.v. injection of 34-1-2s. Black boxes in top pictures outline the enlarged area below. White arrowheads 
point to areas of separation of vascular endothelium from basement membrane. Bars: (F) 70 µm; (I) 2 µm. (J) BALB/c male mice ages 8 and 18 wk (four 
mice per group) were injected i.v. with 34-1-2s or control mAb, and lungs were harvested for evaluation of percent water content 30 min later. Data are 
representative of two experiments. (K) BALB/c male mice (five to six mice per group) were injected i.v. with 34-1-2s or control mAb, and Penh was evalu-
ated over a 1,440-min period. Data are representative of two experiments. (L) BALB/c male mice (five to six mice per group) were injected i.v. with 34-1-2s 
or control mAb, and lungs were harvested for evaluation of percent water content 0, 30, 120, and 1,440 min later. Data are representative of two experi-
ments. *, P < 0.05 using a nonparametric two-tailed t test. Mean ± SEM is shown.
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that  BALB/c  background  FcR-deficient  mice  developed 
only slightly less severe disease than WT mice (Fig. 2 A, left). 
A greater defect was observed in FcR-deficient mice of a 
mixed C57BL/6 × BALB/c background (Fig. 2 A, right), sug-
gesting a role for genetic background in FcR contribution 
to mTRALI susceptibility. Surprisingly, mice deficient in the 
stimulatory FcRs FcRIII (Fig. 2 B), FcRI (Fig. 2 C), or 
both FcRI and FcRIII (Fig. 2 D) still developed severe 
mTRALI, as did FcRI/FcRIII double-deficient mice treated 
with a blocking anti-FcRIV mAb (Fig. 2 E; Nimmerjahn   
et al., 2005). The trivial effect of deleting or blocking all stimu-
latory FcRs on mTRALI, in fact, raises the possibility that the 
limited FcR participation in mTRALI reflects FcR associa-
tion with an activating receptor other than an FcR, such as 
the IL-3R (Hida et al., 2009), the leukocyte mono-Ig–like re-
ceptor family (Izawa et al., 2009), myeloid-associated Ig-like 
receptor II (Nakahashi et al., 2007), CMRF-35–like molecule-5 
(Fujimoto et al., 2006), platelet glycoproteins VI (Gibbins et al., 
1997; Takaya et al., 2005) and IIb (Wu et al., 2001), den-
dritic cell immunoactivating receptor 
(Kanazawa et al., 2003), natural killer 
receptor P1 (Arase et al., 1997), paired 
Ig-like receptor A (Maeda et al., 1998), 
Toll-like receptor 4 (Rittirsch et al., 
2009), or dectin-2 (Sato et al., 2006).
While  investigating  the  role  of 
stimulatory FcRs in mTRALI, we 
noted that treating mice with the mAb 
2.4G2,  which  cross-links  both  the 
basement membrane, was apparent by 5 min after mAb in-
jection, was not associated with platelet thrombi or neutro-
phil infiltrates (Fig. 1 I), and was never observed in control 
mice. Disease severity, as measured by percent lung water 
weight, was similar in the youngest (8 wk) and oldest (20 wk) 
mice used in our experiments (Fig. 1 J). Both the increase in 
lung water and Penh fully resolved by 24 h after mAb injec-
tion (Fig. 1, K and L). Thus, disease induced by anti–MHC 
class I mAb, mouse TRALI (mTRALI), shares many features 
with human TRALI and is likely caused by rapid damage to 
alveolar capillary walls, followed by leakage of fluid and pro-
tein into the lung parenchyma.
mTRALI has limited dependence on FcRs
A previous study that was performed with BALB/c mice and 
34-1-2s implicated FcRs in mTRALI pathogenesis by dem-
onstrating the failure of 34-1-2s–injected BALB/c background 
FcR-deficient mice (which lack all stimulatory FcRs; Takai 
et al., 1994) to develop disease (Looney et al., 2006). We found 
Figure 2.  mTRALI is partially FcR inde-
pendent. (A) BALB/c male mice (14–24 mice 
per group, pooled from four experiments) or 
male mice with a mixed BALB/c and C57BL/6 
background (8–9 mice per group, pooled from 
two experiments) that were FcR sufficient 
(FcR+/+) or deficient (FcR/) were injected 
i.v. with 34-1-2s or control mAb. Penh was 
evaluated for this and all other experiments  
in this figure. Lungs harvested 30 min after 
challenge were evaluated for water content in 
this and all other experiments in this figure.  
(B) FcRIII+/+ and FcRIII/ male mice (six 
mice per group) were injected i.v. with 34-1-2s 
or control mAb. Results are representative of  
at least two experiments for this and all subse-
quent panels in this figure. (C) FcRI+/+ and 
FcRI/ male mice (six mice per group) were 
injected i.v. with 34-1-2s or control mAb.  
(D) FcRI/III+/+ and FcRI/III/ male mice (four 
mice per group) were injected i.v. with 34-1-2s 
or control mAb. (E) FcRI/III/ male mice (four 
mice per group) were injected i.v. with anti-
FcRIV mAb or isotype control mAb and then 
challenged the next day with 34-1-2s or iso-
type control mAb. *, P < 0.05; **, P < 0.005; and 
***, P < 0.0005 using a nonparametric two-
tailed t test. Mean ± SEM is shown.JEM Vol. 208, No. 12 
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whether other Ig-related effector mechanisms might be in-
volved. Because mouse IgG2a mAbs activate complement 
as well as FcRs (Köhl and Gessner, 1999; Schmidt and 
Gessner,  2005),  we  evaluated  whether  the  complement 
system  is  required  for  anti–MHC  class  I  mAb–induced 
mTRALI. We observed C3 binding to lung cells soon after 
34-1-2s injection (Fig. 4 A) and found an absolute require-
ment for C3 (Fig. 4 B), C5 (Fig. 4 C), and C5aR but not 
C3aR (Fig. 4 D) for mTRALI development. Deficiency of 
a second C5a receptor, C5L2, partially decreased mTRALI 
severity (Fig. 4 E). These results suggested an explanation 
for what appeared to us to be a limitation of the mTRALI 
model: mTRALI is induced by 34-1-2s injection in male 
but not female BALB/c mice (Fig. 5 A), whereas TRALI 
develops with similar frequency in men and women (Silliman 
et al., 2003b; Toy et al., 2004). Because C5 levels are con-
siderably higher in mature male mice than female mice 
(Fig. 5 B; Churchill et al., 1967; Baba et al., 1984) or pre-
pubertal males (Fig. 5 C; Cinader et al., 1964; Baba et al., 
1984) and mature males have a molecular species of C5 
that is absent in female or prepubertal male mice (differ-
ences not seen in humans; Baba et al., 1984), we evaluated 
whether transfer of plasma from male mice would make 
stimulatory  receptor  FcRIII  and  the  inhibitory  receptor 
FcRIIb (Unkeless, 1979; Clynes et al., 1999; Strait et al., 
2002; Hirano et al., 2007), completely prevented the develop-
ment of mTRALI in WT mice (Fig 3 A). This result, taken 
together with our observations about the limited role of stimula-
tory FcRs in mTRALI pathogenesis, suggests that 2.4G2 in-
hibits mTRALI by activating the inhibitor receptor, FcRIIb, 
rather than by blocking FcRIII. Consistent with this possibil-
ity, mTRALI was blocked in WT but not FcRIIb-deficient 
mice treated with an FcRIIb-specific mAb, anti-Ly17.2   
(Fig. 3 B; Gessner et al., 1998; Schiller et al., 2000), and in 
FcRI/RIII-deficient  mice  (Fig.  3  C)  but  not  FcRIIb- 
deficient mice (Fig. 3 D) treated with 2.4G2. However, WT 
and FcRIIb-deficient mice developed mTRALI similarly if 
not treated with an anti-FcRIIb mAb (Fig. 3, B and D). Col-
lectively, these results demonstrate that stimulatory FcRs have 
a limited role in mTRALI pathogenesis and that FcRIIb does 
not typically regulate mTRALI development but can suppress 
this disorder if activated before anti–MHC class I mAb injection.
mTRALI pathogenesis is C5a and C5aR dependent
Our negative observations about stimulatory FcRs’ im-
portance  in  mTRALI  pathogenesis  led  us  to  investigate 
Figure 3.  Suppression of mTRALI by FcRIIb ligation. (A) BALB/c male mice (four to eight mice per group) were pretreated s.c. with 2.4G2 (rat IgG2b 
anti-FcRII/III mAb) or control mAb and then injected i.v. the next day with 34-1-2s or control mAb. Penh and percent water weight of lungs were mea-
sured for this and all other experiments in this figure. Results are representative of at least two experiments for this and all subsequent panels in this 
figure. (B) BALB/c FcRIIb+/+ and FcRIIb/ male mice (four mice per group) were pretreated i.p. with mouse IgG2a anti-Ly17.2 mAb (anti-FcRIIb mAb) 
or isotype control mAb and then injected i.v. the next day with 34-1-2s or isotype control mAb. (C) FcRI/III/ male mice (four mice per group) were 
pretreated s.c. with anti-FcRII/III mAb or control mAb and then injected i.v. the next day with 34-1-2s. (D) BALB/c FcRIIb+/+ or FcRIIb/ male mice  
(six mice per group) were pretreated s.c. with anti-FcRII/III mAb or control mAb and then injected i.v. the next day with 34-1-2s or control mAb. *, P < 0.05; 
and **, P < 0.005 using a nonparametric two-tailed t test. Mean ± SEM is shown.2530 Mediators of transfusion-related acute lung injury | Strait et al.
plasma reconstituted the ability of C5-deficient male mice 
to develop mTRALI (Fig. 5 J). Further experiments dem-
onstrated  that  the  typical  pulmonary  vascular  basement 
membrane lesions of mTRALI failed to develop in 34-1-
2s–challenged female mice (Fig. 6 A), unless they were re-
constituted with plasma from male mice (Fig. 6 B), that this 
lesion failed to develop in 34-1-2s–injected C5aR-deficient 
males (Fig. 6 C), and that LPS pretreatment did not restore 
the ability of C3-deficient mice to develop mTRALI (Fig. 6 D), 
even though it increased the sensitivity of WT male mice 
to 34-1-2s (Fig. 6 E). Collectively, these observations dem-
onstrate a critical role for complement, including C5a and 
the C5aR, in mTRALI pathogenesis in both healthy mice 
and in mice with underlying lung injury.
females TRALI susceptible. Indeed, anti–H-2d mAb–injected 
female BALB/c mice developed mTRALI if they were first 
administered plasma from WT or C3-deficient male mice 
but  not  plasma  from  WT  female  mice  or  C5-deficient 
males (Fig. 5 D). Prepubertal male mice, like female mice, 
failed to develop mTRALI in response to 34-1-2s (Fig. 5 E). 
Additional experiments demonstrated that FcR deficiency 
had no effect on C3 or C5 levels (Fig. 5 F), that male and 
female mice had similar plasma C3 levels (Fig. 5 G), that 
transfer of plasma from FcR-deficient male mice to WT 
males did not inhibit mTRALI (Fig. 5 H), that heat treat-
ment, which destroys complement, prevented the ability of 
WT male plasma to reconstitute female mice for mTRALI 
development (Fig. 5 I), and that transfer of C5-sufficient 
Figure 4.  mTRALI is C5 and C5aR dependent. (A) BALB/c male mice (four mice per group) were injected i.v. with 34-1-2s or control mAb, and 
lungs were harvested 5, 15, and 30 min later. Deposition of C3 (bright green) in lung sections was evaluated by immunofluorescence staining. Repre-
sentative slides are shown. Bars, 70 µm. (B) Mixed genetic background H-2d C3+/+ and C3/ male mice (four mice per group) were injected i.v. with 
34-1-2s or control mAb. Penh was evaluated in this and all subsequent panels in this figure. Lungs harvested 30 min after challenge were evaluated 
for percent water content in this and all subsequent panels in this figure. Results are representative of at least two experiments for all panels in this 
figure except as noted. (C) B10.D2 C5+/+ and C5/ male mice (four to eight mice per group) were injected i.v. with 34-1-2s or control mAb. (D) BALB/c 
WT, C5aR/, and C3aR/ male mice (four to eight mice per group) were injected i.v. with 34-1-2s or control mAb. Penh is only shown for 34-1-2s–
injected mice in this and subsequent panels in this figure. (E) BALB/c male mice sufficient (WT) or deficient for the C5a receptor, C5L2 (C5L2/; four 
mice per group) were injected i.v. with 34-1-2s or control mAb. This experiment was performed once. *, P < 0.05; and **, P < 0.005 using a nonpara-
metric two-tailed t test. Mean ± SEM is shown.JEM Vol. 208, No. 12 
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Monocytes, not neutrophils or platelets,  
are required for mTRALI
Two publications suggest that neutrophils and platelets are 
required for 34-1-2s–induced mTRALI and cause disease by 
producing ROIs in response to FcR stimulation (Looney   
et al., 2006, 2009). Our demonstrations that disease is mediated 
Figure 5.  Low C5 levels prevent develop-
ment of mTRALI in female mice. (A) BALB/c 
male and female mice (six mice per group) 
were injected i.v. with 34-1-2s or control 
mAb. For this and all subsequent experiments 
in this figure, except B and C, Penh was evalu-
ated, and lungs harvested 30 min after chal-
lenge were evaluated for percent water 
content. Results are representative of at least 
two experiments for all panels in this figure. 
(B) Relative plasma C5 content was deter-
mined by ELISA for B10.D2 C5+/+ male and 
female and C5/ male mice (12 mice per 
group). (C) Relative plasma C5 content (12 mice 
per group) was determined by ELISA for 3.5-wk-
old (prepubertal) or 8-wk-old (adult) WT male 
mice. (D) BALB/c female mice (four to eight 
mice per group) were pretreated i.v. with sa-
line (none) or plasma from male or female WT 
mice, male C5/ mice, or male C3/ mice 
and then injected i.v. with 34-1-2s. (E) Adult 
and prepubertal male mice (four mice per 
group) were injected i.v. with 34-1-2s or con-
trol mAb. (F) BALB/c WT and FcR-deficient 
(FcR/) and mixed background C3-deficient 
(C3/) and B10.D2 C5-deficient (C5/) male 
mice had their plasma C3 and C5 levels mea-
sured by ELISA (n = 5 mice per group for C3 
and n = 12 mice per group for C5; ND = none 
detected). (G) BALB/c male and female and 
mixed background C3-deficient male mice 
had their plasma C3 levels measured by ELISA 
(five mice per group). (H) BALB/c male mice 
were pretreated with plasma from male 
FcR/ mice before i.v. challenge with 34-1-2s 
or control mAb. (I) BALB/c female mice  
(four mice per group) pretreated with normal 
or heat-inactivated plasma from WT male 
before i.v. challenge with 34-1-2s or control 
mAb. (J) B10.D2 C5-deficient male mice (four 
mice per group) were pretreated with plasma 
from C5-deficent or -sufficient male mice 
before i.v. challenge with 34-1-2s or control 
mAb. *, P < 0.05; and **, P < 0.005 using a 
nonparametric two-tailed t test. Mean ± SEM 
is shown.
predominantly through C5a rather than any single FcR and 
that  FcRIIb  ligation  can  suppress  mTRALI  suggested  a 
need to reexamine these conclusions with the view that Abs 
used to eliminate neutrophils or platelets might interfere with 
mTRALI by depleting complement or desensitizing effec-
tor cells through a stimulatory or inhibitory receptor. In-
jection of BALB/c mice with a single 
dose of a depleting rabbit anti–mouse 
platelet Ab 4 h before 34-1-2s injection 
confirmed the previous report that 
this  treatment  suppresses  mTRALI   
(Fig. 7 A; Looney et al., 2009); however,   2532 Mediators of transfusion-related acute lung injury | Strait et al.
Figure 6.  Association of mTRALI with complement in untreated and LPS-pretreated mice. (A) BALB/c male and female mice (four mice per 
group) were challenged i.v. with 34-1-2s; lungs were harvested 0, 0.5, or 48 h later. In this and all subsequent panels, black boxes in left photographs 
outline the enlarged area immediately to the right, and black arrowheads point to the region of separation of vascular endothelium from its basement 
membrane. (B) BALB/c female mice (four mice per group) were injected i.v. with female or male plasma and then injected i.v. with 34-1-2s. Lungs were 
harvested 30 min later. (C) BALB/c C5aR-deficient mice (four mice per group) were challenged i.v. with 34-1-2s; lungs were harvested 30 min later.  
(A–C) Representative electron micrographs of lungs are shown. Bars, 2 µm. (D) Mixed genetic background H-2d/d male C3+/+ and C3/ mice (four mice 
per group) were inoculated i.t. with 3 µg LPS and challenged i.v. 3 d later with 34-1-2s. Penh was evaluated for the next 26 min. Lungs were harvested  
30 min after injection and evaluated for percent water content. (E) BALB/c male mice (four mice per group) were initially left untreated or inoculated i.t. 
with 2 µg LPS and challenged i.v. 3 d later with 8 µg 34-1-2s or control mAb. Penh was evaluated for the next 24 h. (D and E) A repeat experiment gave 
similar results. *, P < 0.05 using a nonparametric two-tailed t test. Mean ± SEM is shown.JEM Vol. 208, No. 12 
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N-acetylcysteine (Hidalgo et al., 2009), a result which we 
confirmed (Fig. 8 A). Because monocytes and macrophages 
are capable of generating ROIs in response to C5a, we studied 
whether these cells are required for 34-1-2s induction of 
mTRALI. Depletion or inactivation of monocyte/macrophages 
was accomplished by i.v. injection of gadolinium or clodro-
nate-loaded liposomes. Gadolinium aggregates in blood and 
is  subsequently  phagocytosed  by  monocytes  and  macro-
phages, inducing anergy and apoptosis (Singh and de la 
Concha-Bermejillo, 1998; Frid et al., 2006; Thenappan et al., 
2011). Clodronate-loaded liposomes similarly kill monocytes 
and macrophages that ingest them (Thepen et al., 1989; Ajuebor 
et al., 1999; Popovich et al., 1999; Wang et al., 1999; Nikolic 
et al., 2005; Farley et al., 2006; Bhatia et al., 2011). Pretreat-
ment with i.v. gadolinium or i.p. plus intratracheal (i.t.) 
clodronate-containing  liposomes  totally  suppressed  mTRALI 
(Fig. 8, B and C). To compare the roles of blood monocytes 
with resident lung macrophages in mTRALI pathogenesis, 
we selectively depleted either of the two populations by ad-
ministering gadolinium i.v. or clodronate-containing liposomes 
i.p. (to deplete blood monocytes) or i.t. (to deplete resident 
lung macrophages) and found that mTRALI was suppressed 
by the i.v. and i.p. but not the i.t. treatments (Fig. 8, D and E). 
Thus, peripheral blood monocytes appear to be required for 
mTRALI and, most likely, are the source of ROIs that con-
tribute to disease development.
Targeting of non-BM–derived cells by anti–MHC class I 
mAb is required for mTRALI induction
Identification of peripheral blood monocytes as the inflam-
matory cell type required for mTRALI induction left open 
the possibility that noninflammatory lung cells, such as vascular 
endothelial cells, had to be targeted by anti–MHC class I mAb 
to direct inflammatory cells to the lungs. After first demon-
strating that 34-1-2s binds to lung vasculature by 1 min 
after i.v. injection (Fig. 8 F), we used H-2d BM chimeric 
mice to directly evaluate whether 34-1-2s binding to non-
BM–derived cells is essential for mTRALI pathogenesis in 
our model. mTRALI developed in mice that expressed   
H-2d on all cell types and mice that expressed H-2d predomi-
nantly on non-BM–derived cells (although they still had a 
small percentage of H-2d+ neutrophils) but failed to develop 
in mice that selectively lacked H-2d on non-BM–derived 
cells and mice that totally lacked H-2d (Fig. 8 G). Thus, 
anti–H-2d mAb appears to initiate mTRALI predominantly 
by binding to non-BM–derived cells, such as vascular endo-
thelial cells. In addition, the use of RAG2-deficient mice in 
this chimera experiment demonstrates that neither B nor   
T cells are required for the development of mTRALI.
mAb requirements for mTRALI induction
One remaining question about mTRALI induction by 34-1-2s 
is why this is the only anti–H-2d mAb that induces mTRALI 
of eight IgG2a and IgM anti–H-2d mAbs tested (Fig. 9 A). 
One  obvious  possibility  was  that  34-1-2s  was  the  only 
mAb of our set that binds to both H-2Dd and H-2Kd.   
injection of this Ab 24 and 48 h before 34-1-2s challenge 
still depleted platelets (Fig. 7 B) but no longer suppressed 
mTRALI (Fig. 7 A). This is consistent with the possibility 
that mTRALI is suppressed by the formation of platelet/ 
antiplatelet Ab immune complexes that deplete complement, 
activate FcRIIb, and/or desensitize effector cells by mecha-
nisms other than platelet elimination. Presumably, immune 
complex effects dissipate by 2 d after the initial antiplatelet Ab 
injection, while slow regeneration of platelets limits new im-
mune complex production. To confirm that platelets are not 
required for mTRALI, we evaluated whether platelet deple-
tion by a nonimmune mechanism, injection of neuramini-
dase, could block mTRALI and again found that mTRALI 
developed despite platelet absence (Fig. 7, C and B, respec-
tively). This is consistent with the ultrastructural finding that 
platelets were not observed in the alveolar capillary wall le-
sions (Fig. 1 I and Fig. 6, A and B).
Because neutrophils had also been implicated in mTRALI 
pathogenesis primarily through studies that used a relatively 
high dose of mAb to deplete these cells (Looney et al., 2006, 
2009), it seemed possible that suppression of mTRALI was 
again caused by immune complex formation rather than by 
depletion of a cell required for disease pathogenesis. Consis-
tent with published reports (Looney et al., 2006, 2009), we 
found that mTRALI was suppressed by injection of a high 
dose of anti-Ly6C/6G mAb (anti–Gr-1) before injection of 
34-1-2s (Fig. 7 D, bottom). However, in contrast to our ex-
periments with platelets, repeated injection of anti-Ly6C/6G 
mAb on successive d before 34-1-2s challenge still suppressed 
mTRALI (not depicted). Because Ly6C/6G mAb incom-
pletely depletes splenic neutrophils (unpublished data), this 
did not completely disprove the possibility that Ly6C/6G 
mAb suppression of mTRALI was caused by immune com-
plex generation rather than neutrophil depletion. To further 
study this possibility, we evaluated the ability of a combina-
tion of low-dose anti-Ly6C/6G mAb and the alkylating 
agent  hydroxyurea  to  suppress  both  the  blood  neutrophil 
count and the migration of neutrophils to the lungs after 
34-1-2s injection and mTRALI induction. Although the   
combination of low-dose anti-Ly6C/6G mAb and hydroxy-
urea was even more effective than high-dose anti-Ly6C/6G 
mAb at eliminating neutrophils in blood (Fig. 7 D, top left) 
and  also  blocked  the  34-1-2s–induced  increase  in  lung 
neutrophils (Fig. 7D, top right), this combination failed to 
suppress mTRALI (Fig. 7 D, bottom). To confirm that im-
mune complex formation can suppress mTRALI, we injected 
mice with an anti-erythrocyte lineage mAb (Jordan et al., 
2003) 1 d before 34-1-2s challenge and found total suppres-
sion of disease development (Fig. 7 E), even though it seems 
unlikely that erythrocytes or their precursors are involved in 
mTRALI pathogenesis.
Elimination of neutrophils and platelets as cells essential 
for mTRALI pathogenesis raised the question of what cells 
are involved. A previous study found that mTRALI patho-
genesis involves generation of ROIs, as shown by suppression 
of mTRALI in mice pretreated with the reducing agent   2534 Mediators of transfusion-related acute lung injury | Strait et al.
Figure 7.  Neither platelets nor neutrophils are required for mTRALI pathogenesis. (A) BALB/c male mice (four mice per group) were pretreated i.v. 
with saline or rabbit antiplatelet pAb (anti-plt) both 24 and 48 h before or only 4 h before injection i.v. with 34-1-2s or control mAb. In all panels in this 
figure except B, Penh was evaluated, and then lungs were harvested 30 min after 34-1-2s injection and evaluated for percent water content. Results are 
representative of at least two experiments for all panels in this figure except as noted. (B) BALB/c male mice (4–10 mice per group) were injected i.v. with 
rabbit antiplatelet pAb 4 h or both 24 and 48 h before determination of peripheral blood platelet count or with neuraminidase or saline 24 h before de-
termination of peripheral blood platelet count. (C) BALB/c male mice (four to eight mice per group) were pretreated with neuraminidase or saline i.p. 1 d JEM Vol. 208, No. 12 
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However, this possibility was eliminated by experiments that 
showed that 34-1-2s induced mTRALI in B10A-H2a mice, 
which express H-2Dd but not H-2Kd (Fig. 9 B). Another 
possibility was that 34-1-2s had a higher avidity for H-2d than 
any of the other mAbs. This would be consistent with a re-
cent human study that associates the development of TRALI 
with the presence of high-avidity anti-HLA Ab (Hashimoto 
et al., 2010). Although avidity is probably important in our 
mouse model, 34-5-8s and SF1-1.1.10 also bound with high 
avidity, based on the quantity of mAb required for half-
maximal staining of BALB/c spleen cells (Fig. 9 C), yet they 
both failed to induce mTRALI by themselves (Fig. 9 A). A 
third possibility, supported by the data in Fig. 9 C, was that 
more 34-1-2s bound to BALB/c spleen cells than any of the 
other anti–H-2d mAbs tested. Consistent with this possi-
bility, 34-1-2s also activated complement to a greater extent 
than any of the other anti–H-2d mAbs tested, as shown by 
C3d binding to nucleated blood cells (Fig. 9 D); however, 
we cannot prove that this is the critical feature that makes 
34-1-2s pathogenic. Although we also tried to evaluate whether 
34-1-2s could increase serum levels of C5a faster than any   
of the other anti–H-2d mAbs, we have been unable to re-
producibly quantitate C5a in plasma, possibly because of its 
short half-life.
However, the possibility that 34-1-2s pathogenicity is re-
lated to rapid complement activation predicted that injection 
of a nonpathogenic anti–H-2d mAb before injection of 34-1-2s 
might suppress mTRALI development by depleting comple-
ment. Indeed, injection of either of the nonpathogenic anti–
H-2d  mAbs,  SF1-1.1.10  or  34-5-8s,  which  do  not  block 
34-1-2s binding to H-2d (Fig. 9 E, left), 2 h before 34-1-2s 
suppressed mTRALI (Fig. 9 E, middle and right). In contrast, 
simultaneous injection of a nonpathogenic anti–H-2d mAb 
with 34-1-2s, which should increase total mAb binding and 
accelerate complement activation, increased mTRALI sever-
ity and complement binding (Fig. 9 F). Consistent with this, 
injection of BALB/c mice simultaneously with a cocktail of 
nonpathogenic anti–H-2d mAbs that bind to different H-2d 
epitopes increased the activation of complement as measured 
by C3d binding to peripheral nucleated blood cells (not de-
picted) and induced mTRALI (Fig. 9 G). Collectively, these 
observations suggest that the rapid focusing of a relatively 
large quantity of IgG mAb onto specific epitopes of vascular 
endothelial H-2d molecules is required to induce C5a pro-
duction with sufficient rapidity to stimulate macrophage/
monocyte migration to the lungs and ROI secretion and, 
consequently, sufficient damage to vascular endothelial cells 
to cause clinically apparent disease (diagramed in Fig. 10).
DISCUSSION
Although TRALI can be induced by at least two different mech-
anisms, both of which increase pulmonary vascular permeability, 
we have confined our study to a mouse model of alloantibody-
induced TRALI.  Our  studies  with  this  model  confirm  and   
extend a previously described observation (Looney et al., 2006, 
2009): a disorder very similar to human TRALI can be induced 
by injecting mice with an mAb against MHC class I, with rapid 
disruption of the alveolar capillary wall, fluid and protein leak 
into the lungs, a change in breathing mechanics, and a decrease 
in blood neutrophil count. However, although our experiments 
use the same mAb and mouse strain as other publications, they 
reveal a very different pathogenic mechanism than has been pro-
posed. First, we find that almost complete depletion of neutro-
phils or platelets from BALB/c mice has no effect on the ability 
of 34-1-2s to induce mTRALI, conclusions which are consis-
tent with our ultrastructural findings that neither cell type is ob-
served in the vicinity of the alveolar capillary wall lesions. We 
agree with published reports that injection of mice with a rabbit 
antiplatelet pAb or a high dose of a rat mAb to Ly6C and Ly6G 
(anti–Gr-1) acutely prevents mTRALI (Looney et al., 2006, 
2009). However, injection of either Ab forms immune com-
plexes with platelets or neutrophils that may inhibit mTRALI by 
consuming complement or binding to inhibitory or stimulatory 
FcRs. We hypothesized that this process, rather than loss of 
platelets or neutrophils, was responsible for mTRALI inhibition. 
Indeed, formation of mAb complexes with erythrocytes and 
erythrocyte precursors had the same effect, even though it is 
unlikely  that  erythrocyte  lineage  cells  participate  directly  in 
mTRALI pathogenesis. Furthermore, repeated injection of 
rabbit antiplatelet Ab, which maintains thrombocytopenia in 
the absence of further immune complex production (because 
of the time required to produce more platelets), does not inhibit 
mTRALI. Neither does platelet depletion by a nonimmune 
mechanism (injection of neuraminidase) inhibit mTRALI.
Testing the hypothesis that neutrophils are not required 
for mTRALI proved more difficult; the incomplete deple-
tion of splenic neutrophils by anti–Gr-1 mAb did not allow 
this same strategy to be used to deplete blood neutrophils 
without maintaining immune complex production. Instead, 
we used a combination of low-dose anti–Gr-1 mAb and the 
before i.v. injection with 34-1-2s or control mAb. (D) BALB/c male mice (four to eight mice per group) were pretreated with saline or hydroxyurea i.p. daily 
on day 0–6 and/or anti-Ly6G/C mAb i.v. at a dose of either 0.1 mg (Lo) on days 5 and 6 or 1 mg (Hi) on day 6. On day 7, mice were bled for determination 
of absolute neutrophil count (ANC; top left) or injected i.v. with 34-1-2s or control mAb (bottom). Penh values for control mAb-injected mice were all  
<1 (not depicted). In addition, some mice (10 mice per group; top right) were left untreated or were treated i.p. daily with hydroxyurea from day 0 to 6 and 
with low-dose anti-Ly6G/C mAb on days 5 and 6. On day 7, all mice were challenged i.v. with 34-1-2s, and lungs were harvested before or 30 s or 30 min 
after i.v. 34-1-2s injection. The number of neutrophils per high power field was determined for 10 fields of H&E-stained lung sections from each mouse. 
The quantitation of lung neutrophils part of the experiment was performed once. (E) BALB/c male mice (four to five mice per group) were pretreated i.p. 
with TER119 (rat IgG2b anti-RBC mAb) or isotype control mAb and injected i.v. 24 h later with 34-1-2s or control mAb. *, P < 0.05; and **, P < 0.005 using 
a nonparametric two-tailed t test. Mean ± SEM is shown.
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Figure 8.  Involvement of ROIs, monocytes, and non-BM–derived cells in mTRALI pathogenesis. (A) BALB/c male mice (four mice per group) were 
pretreated i.v. with N-acetylcysteine (NAC) or saline and injected i.v. 5 min later with 34-1-2s or control mAb. In all panels, except for D and F, Penh was 
evaluated and then lungs were harvested 30 min after 34-1-2s injection and evaluated for percent water content. Results are representative of at least 
two experiments for this and all subsequent experiments in this figure. (B) BALB/c male mice (five to eight mice per group) were pretreated i.v. with  
gadolinium or saline and injected i.v. the next day with 34-1-2s. (C) BALB/c male mice (four mice per group) were pretreated i.p. and i.t. with liposomes 
containing clodronate or PBS and injected i.v. 2 d later with 34-1-2s or control mAb. (D) BALB/c male mice (four mice per group) were injected with 
liposome-encapsulated clodronate (Clod) or PBS i.p. or i.t. Absolute monocyte count was determined for blood obtained 2 d later. Another group was 
injected i.v. with gadolinium (Gd). Blood was drawn the next day, and absolute monocyte count was determined. (E) BALB/c male mice (four mice per 
group) were injected with liposome-encapsulated clodronate or PBS either i.p. or i.t. and challenged i.v. 2 d later with 34-1-2s. (F) BALB/c male mice (four 
mice per group) were injected i.v. with biotinylated 34-1-2s or control mAb. Lungs were obtained 60 s later and stained for biotin (brown). Representative JEM Vol. 208, No. 12 
Article
2537
blocking the stimulatory receptors FcRI, FcRIII, or FcRIV. 
Inhibition of mTRALI by FcRIIb activation was confirmed 
by demonstrating that this disorder could also be suppressed 
in WT but not FcRIIb-deficient mice by treatment with an 
FcRIIb-specific anti-Ly17.2 mAb.
In contrast to a previous study (Looney et al., 2006), our 
observations establish a critical role for complement, particu-
larly C5a, in this disorder. mTRALI fails, in our hands, to 
develop in mice deficient in C3, C5, or the C5aR, although 
Looney et al. (2006) described normal disease development 
in C5aR-deficient mice. It is possible that differences in animal 
husbandry and/or bacterial flora account for our different re-
sults. Additionally, the use of general anesthesia for anti–H-2d 
mAb–treated mice in the study by Looney et al. (2006), but 
not in our experiments, could influence lung physiology and 
possibly disease development. More importantly, the require-
ment for C5 in our experiments explains why 34-1-2s injec-
tion induces mTRALI in adult male but not female BALB/c 
mice, which have only 25% as much plasma C5 as males. 
In addition, male mice have a form of C5 that is totally lack-
ing in females (Baba et al., 1984). This quantitative and quali-
tative gender dimorphism for C5 explains the male/female 
difference in mTRALI susceptibility, as shown by our exper-
iments in which female mice became susceptible to mTRALI 
induction  when  first  infused  with  plasma  from  WT  or   
C3-deficient male mice but not when infused with plasma 
from WT females or C5-deficient males. These observations 
are consistent with the lack of a gender difference in human 
TRALI susceptibility, inasmuch as there are no known gen-
der differences in human plasma C5 levels.
Although our disease pathogenesis experiments have been 
restricted to a mouse model of TRALI, the immune com-
plex–related artifacts that we have uncovered are probably 
not specific to studies of this disorder. In fact, we have previ-
ously shown that IgG–platelet complexes caused secondary 
effects that mistakenly suggested that platelets are essential for 
IgG-mediated murine anaphylaxis (Strait et al., 2002). We 
suspect that immune complex–mediated complications may 
confuse investigation of several disease models, as can the 
mistaken  assumption  that  abnormalities  in  FcR-deficient 
mice necessarily reflect a requirement for IgG or IgE recep-
tors (FcRI, FcRIII, FcRIV, and/or FcRI).
In addition to establishing critical roles for monocytes and 
C5a and confirming a role for ROIs in mTRALI pathogene-
sis, we show that MHC class I must be expressed on non-BM–
derived cells (most likely pulmonary vascular endothelium) 
for mTRALI induction by 34-1-2s. This vascular endothelial 
location is particularly interesting in view of a report of TRALI 
induced solely in the transplanted lung of a posttransplant   
alkylating agent hydroxyurea to fully deplete blood neutro-
phils and prevent their appearance in the lungs without gen-
erating sufficient immune complex to suppress TRALI.
In contrast to the lack of a requirement for either platelets 
or neutrophils in TRALI pathogenesis, development of this 
disorder required functional peripheral blood monocytes, as 
demonstrated by studies that prevented TRALI by these cells 
with clodronate-containing liposomes (Thepen et al., 1989; 
Popovich et al., 1999; Wang et al., 1999; Jordan et al., 2003; 
Murphy et al., 2004; Nikolic et al., 2005; Farley et al., 2006; 
Zhao et al., 2006; Bhatia et al., 2011) or inactivating and 
depleting them with gadolinium (Singh and de la Concha-
Bermejillo,  1998;  Strait  et  al.,  2002;  Frid  et  al.,  2006;   
Thenappan et al., 2011). The requirement for monocytes is 
consistent with an essential role in mTRALI for ROIs, which 
are produced by activated monocytes/macrophages.
Our experiments also differ from published results by 
questioning the importance of FcRs in mTRALI patho-
genesis. The previously reported conclusion that FcRs 
are required for TRALI pathogenesis (Looney et al., 2006) 
was based on the observation that mTRALI is not induced 
by 34-1-2s injection in FcR-deficient mice, which lack 
all stimulatory FcRs. Studies with FcR-deficient mice 
have the advantage that this polypeptide is an essential part 
of all stimulatory FcRs in the mouse, so that FcR deficiency 
simultaneously prevents FcRI, FcRIII, FcRIV, and FcRI 
function. However, we found that mTRALI still occurs 
with only a minor decrease in severity in BALB/c FcR-
deficient mice and with a greater decrease in severity in 
FcR-deficient mice that have a mixed BALB/c – C57BL/6 
genetic background. More importantly, because FcR also 
associates with many other receptors and influences or is 
required for their signaling, the absence of mTRALI in 
FcR-deficient mice does not necessarily indicate FcR 
involvement. The development of mTRALI to nearly the 
same degree in B10.D2 FcRI/III double-deficient mice 
pretreated with a blocking anti-FcRIV mAb as in un-
treated WT mice supports the conclusion that stimulatory 
FcRs are not essential in mTRALI pathogenesis.
Our observation that mTRALI can be blocked by pre-
treating mice with 2.4G2, which activates and then blocks 
FcRIIb, FcRIII, and possibly FcRIV (Unkeless, 1979; 
Clynes et al., 1999; Strait et al., 2002; Hirano et al., 2007), 
initially seemed to support a role for stimulatory FcRs in 
mTRALI pathogenesis. However, our subsequent experi-
ments  revealed  that  2.4G2  blocks  mTRALI  in  WT  and 
FcRI/RIII-deficient mice but not in mice deficient in the 
inhibitory receptor, FcRIIb. Thus, 2.4G2 inhibits mTRALI 
by giving a negative signal to cells via FcRIIb rather than by 
sections are shown. Bars, 70 µm. (G) BALB/c (H-2d) and C57BL/6 (H-2b) RAG2-deficient male mice (four mice per group) were lethally irradiated and in-
jected i.v. the next day with BM cells from RAG2-deficient H-2d or H-2b mice. 6 wk later, H-2d+ blood neutrophil counts were determined. 1 wk after that, 
mice were injected i.v. with 34-1-2s. An experiment in which BM chimeras were produced by reconstituting irradiated BALB/c or C57BL/6 mice with BM 
from (BALB/c × C57BL/6) F1 mice and challenged with 34-1-2s gave nearly identical results. Horizontal bars indicate the mean. *, P < 0.05; and  
**, P < 0.005 using a nonparametric two-tailed t test. Mean ± SEM is shown.
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mechanism for mTRALI induction (diagramed in Fig. 10): 
Abs binding to MHC class I on pulmonary vascular endothe-
lial cells activate complement with the production of C5a, 
which  is  chemotactic  for  monocytes/macrophages  and   
additionally activates them to release 
ROIs, which rapidly damage the endo-
thelial cells. It is additionally possible 
that complement activation also di-
rectly damages endothelial cells (al-
though not enough to induce TRALI 
in  the  absence  of  macrophages  or 
ROIs), that the small size of pulmonary   
patient by donor plasma that contained Abs reactive with 
MHC antigens expressed by the lung donor but not by the 
recipient’s native lung (Dykes et al., 2000). Collectively with 
our other observations, this suggests a relatively complex 
Figure 9.  mAb properties required to 
induce mTRALI. (A) BALB/c male mice (four 
mice per group) were challenged i.v. with 
eight different mouse IgG2a anti–H-2d mAbs. 
Mean maximum Penh during the next 26 min 
is shown. Results are representative of at least 
two experiments for all panels in this figure.  
(B) C57BL/10, B10.D2, and B10A-H2a male  
mice (four mice per group) were injected i.v. 
with 34-1-2s or control mAb. For all panels in 
this figure except C and D, Penh was evalu-
ated, and lungs harvested 30 min after injec-
tion were evaluated for percent water 
content. In this panel, Penh values for control 
mAb-injected mice were all <1 (not depicted). 
(C) Spleen cells harvested from BALB/c male 
mice were evaluated in vitro by flow cytom-
etry for neutrophil and CD8+ T cell binding of 
six different mouse IgG2a anti–mouse H-2d 
mAbs to neutrophils (MFI, mean fluorescence 
intensity). (D) BALB/c male mice (four mice 
per group) were challenged i.v. with 34-1-2s, 
34-5-8s, SF1-1.1.10, or control mAb. Blood 
drawn 3 min later was evaluated by flow cytom-
etry for C3 binding to nucleated cells.  
(E) BALB/c male mice (four mice per group) 
were pretreated i.v. with SF1-1.1.10, 34-5-8s, 
or control mAb and injected i.v. 2 h later with 
34-1-2s or control mAb. Blood drawn 3 min 
later from some mice was evaluated for 34-1-2s 
binding to nucleated cells. Penh and percent 
water content of lungs were determined for 
the other mice. (F) BALB/c male mice (four 
mice per group) were injected i.v. with 34-1-2s, 
SF1-1.1.10, 34-1-2s + SF1-1.1.10, or control 
mAb. Some mice were evaluated for abnormal 
breathing (Penh; middle) and percent lung 
water content (right). Mononuclear cells in 
blood drawn from other mice 3 min after mAb 
injection were evaluated by flow cytometry 
for C3 binding (left). (G) BALB/c male mice 
(four mice per group) were injected i.v. with 
control mAbs, 34-1-2s, SF1-1.1.10, 34-5-8s, 
or 34-4-20s, or with the combinations of 
these mAbs shown. *, P < 0.05; and **, P < 0.005 
using a nonparametric two-tailed t test.  
Mean ± SEM is shown.JEM Vol. 208, No. 12 
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anti-MHC Ab titers in human plasma and the likelihood of 
inducing TRALI when infused into a susceptible recipient. 
In addition, they suggest that the anti–MHC class I pAbs 
generated in multiparous women, which should bind to 
multiple epitopes on an MHC class I molecule, should be 
more effective than a single mAb at inducing TRALI.
Although mTRALI could be induced by the simultane-
ous injection of anti–H-2d mAbs that were individually inca-
pable of inducing mTRALI, mTRALI induction by 34-1-2s 
could be prevented by first injecting mice with an anti–H-2d 
mAb that was incapable of inducing mTRALI (Fig. 9 E).   
Although we have not yet identified the mechanism respon-
sible for mTRALI prevention by the initial injection of a 
nonpathogenic  mAb  (it  could  involve  complement  con-
sumption, MHC class I antigen modulation, FcRIIb ac-
tivation, FcRIII-dependent macrophage desensitization, an 
adaptive response by pulmonary vascular endothelium, or a 
combination of these), this phenomenon suggests approaches 
that might be used to reduce the risk of TRALI development 
in susceptible individuals.
Finally, it is necessary to point out two limitations of our 
study. First, clinical epidemiology and animal model studies 
suggest that TRALI can be induced by more than one mech-
anism, with the common feature being induction of a suffi-
cient increase in pulmonary vascular permeability and fluid 
leak into the lung parenchyma to compromise breathing 
and gas exchange (Silliman et al., 1997, 1998, 2009; Kopko 
et al., 2003; Looney et al., 2006, 2009; Gajic et al., 2007; 
Chapman et al., 2009; Fung and Silliman, 2009). Epide-
miologic features that favor an Ab-mediated pathogenesis in-
clude higher incidence of TRALI after transfusion of blood 
from multiparous female than male donors, by the consider-
ably decreased incidence of TRALI in the USA and UK after 
reduction in the use of female donors for plasma (Chapman 
et al., 2009; Eder et al., 2010; Stafford-Smith et al., 2010), 
and the high frequency of anti–MHC class I, anti–MHC class II, 
and  antileukocyte  Abs  that  react  with  recipient  cells  in 
TRALI-associated  donor  blood  (Popovsky  and  Moore, 
1985; Kopko et al., 2003; Kopko, 2004; Toy et al., 2004; 
Silliman et al., 2005; Bux and Sachs, 2007). Ab-mediated 
pathogenesis is also supported by individual case reports, 
including one in which different units of blood from the 
same multiparous donor caused TRALI in multiple recipi-
ents (Kopko et al., 2002). In contrast, other studies have 
shown a relationship between the period of blood storage 
and the likelihood of TRALI development, with increased 
storage causing the production of lipid mediators that can 
increase pulmonary vascular permeability (Silliman et al., 
1998, 2003a,b). This model is compatible with the devel-
opment of TRALI in the absence of detectable alloanti-
bodies in transfused blood and the development of TRALI 
after transfusion of an individual’s own stored blood. In our 
view, both the Ab- and the vasoactive mediator–dependent 
mechanisms are likely to contribute to human disease, and 
disease may be most likely to develop when both etiologies 
are present.
capillaries  relative  to  systemic  capillaries  facilitates  macro-
phage binding and activation, and that the relatively high oxy-
gen tension in the lung makes pulmonary capillaries more 
susceptible than systemic capillaries to oxidative damage.
Our data provide further information about mTRALI 
pathogenesis by evaluating the relative ability of different 
IgG2a anti–H-2d mAbs to induce mTRALI. Surprisingly, 
only 34-1-2s, by itself, induced mTRALI out of eight mAbs 
tested. Although 34-1-2s is the only member of our set of 
anti–H-2d mAbs that binds to both H-2Dd and H-2Kd (Ozato 
and Sachs, 1981; Ozato et al., 1982; Noun et al., 1996), it still 
induced mTRALI in mice that expressed only one of these 
MHC class I molecules (Fig. 9 B). Although 34-1-2s binds to 
MHC class I with higher affinity than some other members 
of our mAb panel, it was not the only mAb that bound with 
high affinity. These observations suggest that it is necessary 
for Ab to bind to MHC class I in sufficient quantity to acti-
vate enough complement with sufficient rapidity to attract 
and activate monocytes/macrophages. Consistent with this 
possibility, we found that mTRALI was induced when mice 
were injected with a combination of anti–H-2d mAbs that, 
by themselves, did not induce mTRALI. We hypothesize 
that the combined binding of these mAbs to different H-2d 
epitopes creates sufficient IgG density to meet the rapid 
complement-activating requirements for mTRALI induction. 
These observations would be consistent with the threshold 
model suggested by some (Bux and Sachs, 2007; Vlaar et al., 
2009) and supported by the finding of a correlation between 
strength of donor anti-HLA Ab and induction of TRALI 
(Hashimoto et al., 2010). These findings may also provide some 
explanation for why there is no simple relationship between 
Figure 10.  Induction of mTRALI by anti–MHC class I mAb. The 
simplest mechanism of mTRALI induction consistent with our data is 
shown. Anti–H-2d mAb (1) binds to H-2d on vascular endothelial cells, activat-
ing complement (2) with production of C5a (3), which binds to the C5aR on 
monocyte/macrophages (4), attracting them to lung vasculature (5) and 
inducing them to secrete ROIs (6), which disrupts pulmonary vascular 
endothelial basement membranes (7), allowing fluid and protein to leak 
into the lung parenchyma (8), causing noncardiogenic pulmonary edema.2540 Mediators of transfusion-related acute lung injury | Strait et al.
-deficient mice were genotyped using a protocol from the Jackson Laboratory. 
FcRI-sufficient and -deficient mice were genotyped using the following 
primers: 5-CTTCCTCTGTGCTCTTCC-3, 5-ATTACATGATTCT-
TACCAGCTTTG-3,  and  5-AAGGATGGAAAGGGAGCCTCT-3. 
FcRIII-sufficient and -deficient mice were genotyped using the following 
primers: 5-CTCGTGCTTTACGGTATCGCC-3, 5-TCCGAAGGCT-
GTGGTGAAACTG-3, and 5-ACTCCCAGATCTACAGGGTCG-3.
mAbs.  Hybridomas  that  produce  the  mouse  anti–H-2d  mAbs  34-1-2s,   
SF1-1.1.10, 34-5-8s, 28-14-8s, 31-3-42, 34-7-23s, 34-7-23s, 34-4-20s, and 
34-2-12s and the rat IgG2a anti-FcRII/III mAb 2.4G2 were purchased 
from the American Type Culture Collection. The rat IgG2b anti–Gr-1 mAb 
(anti-Ly6G/C), RB68c5, and its isotype control, J1.2, were gifts of R. Coffman 
and J. Abrams, respectively (DNAX Corp, Palo Alto, CA). The isotype 
control mouse IgG2a, AI6.2 (anti–human IgD mAb), was a gift of J. Kearney 
(University of Alabama, Birmingham, AL). Hybridomas were grown i.p. in 
pristine primed nude or BALB/c mice. Ascites was collected, and IgG frac-
tions were purified by ammonium sulfate precipitation (25–50% saturated frac-
tion), followed by either affinity purification on protein A–Sepharose with 
MgCl2 elution or cation exchange column chromatography (DE-52; GE 
Healthcare). Fractions that contained the desired mAbs were identified by 
Ouchterlony analysis with isotype-specific pAbs. The rat anti–mouse RBC 
mAb (TER119) was a gift from M. Jordan (CCRF). The purified hamster 
anti–mouse FcRIV mAb 9E9 was a gift of J. Ravetch, whereas an isotype 
control hamster IgG was purchased from eBioscience.
TRALI induction and characterization. All experiments were repeated 
at least once unless otherwise specifically stated. Mice were injected i.v. 
through the tail vein with 125 µg anti–H-2d mAb in 200 µl saline unless 
otherwise specified. Development of a breathing pattern characteristic of 
dyspnea was evaluated with whole body barometric plethysmography 
(Buxco Research Systems) as described in Results. The alteration in breath-
ing pattern is characterized by an increase in an index known as Penh, which 
reflects prolongation of the late phase of expiration and an increased rate of 
pressure change during expiration. An increase in Penh does not precisely 
identify the mechanism responsible for respiratory distress.
Determination of lung water. Mice were anesthetized by i.p. injection of 
sodium pentobarbital and rapidly exsanguinated by complete transection of 
their abdominal aorta and vena cava. Lungs were removed intact, frozen in 
liquid nitrogen, weighed, lyophilized for 24 h, and reweighed. The total 
weight of lung water was determined as the difference between pre- and 
postlyophilization weight. The percentage of lung weight accounted for by 
water was determined by dividing the difference between the pre- and post-
lyophilization weights by the prelyophilization weight and multiplying the 
result by 100%.
Bronchoalveolar lavage (BAL) and protein content. Mice were anes-
thetized by i.p. injection of sodium pentobarbital followed by dissection of 
the neck with isolation of the trachea. Polyethylene catheters (OD = 0.97 mm; 
BD) were inserted into their tracheas through a small slit made with iris 
scissors. Lungs were lavaged three times with 1 ml Ca2+- and Mg2+-free 
HBSS (Lonza) that contained 0.02% EDTA and EGTA. The BAL fluid was 
centrifuged at 1,000 rpm for 5 min at 4°C, and the cell pellets were re-
moved. The cell-free BAL fluid was aliquoted and stored at 80°C. The 
protein content of the BAL fluid was measured according to the manufac-
turer’s instructions using the Pierce Protein Assay (Thermo Fisher Scientific) 
with BSA as standard.
Evaluation of hypoxemia. This was performed by measuring the pO2 of 
blood obtained by intracardiac puncture 15 min after anti–H-2 mAb chal-
lenge with an IRMA blood gas analyzer (RNA Medical).
Histology. After exsanguination under pentobarbital anesthesia, lungs were 
gently inflated in situ with formalin and then excised and fixed in formalin 
Second, although we restricted most of our experiments 
to mice that initially had no lung or vascular abnormalities, 
TRALI is most likely to develop in individuals who have 
preexisting inflammatory conditions. These conditions can 
activate macrophages, making them more likely to secrete 
large amounts of ROIs and cause production of vasoactive 
mediators  and  cytokines  that  may  act  synergistically  with 
ROIs (Gilliss and Looney, 2011). These conditions may also 
promote  direct  Ab-induced,  complement-mediated  endo-
thelial cell damage that can rapidly increase vascular leak to 
levels that result in noncardiogenic pulmonary edema (Gilliss 
and Looney, 2011). Consistent with this, inoculation of mice 
with LPS has been shown to considerably increase sensitivity 
to induction of mTRALI by anti–H-2d and other mAbs that 
react with leukocytes (Fig. 6 E; Khan et al., 2006; Looney   
et al., 2009). Interestingly and relevant to our model, sepsis 
and associated LPS have also been shown to up-regulate the 
expression of C5aRs in lung cells (Riedemann et al., 2002), 
macrophages, and endothelial cells (Hunt et al., 2005). Also 
consistent with this observation are reports that mice kept in an 
especially  clean  environment  lack  mTRALI  susceptibility, 
which is restored by treatment with LPS or housing in an envi-
ronment where they are exposed to a broad bacterial spectrum   
(Lögdberg et al., 2009; Looney et al., 2009). We agree with   
suggestions already in the literature that human TRALI is most 
likely to occur when the effects of preexisting inflammation 
are exacerbated by infusion of vascular endothelial cell– and/or 
leukocyte-reactive Abs and vasoactive mediators to simultaneously 
cause multiple insults to vascular integrity (Shaz et al., 2011).
MATERIALS AND METHODS
Mice. All mice were bred and maintained in a specific pathogen-free colony 
at the Cincinnati Children’s Research Foundation (CCRF) except where 
otherwise stated, and all experiments were approved by the Institutional   
Animal Care and Use Committee. Mice were used between age 8 and 20 wk 
except in one series of experiments that used prepubertal males age 3.5 wk 
(Fig. 5, C and E). BALB/c and FcR-deficient mice were purchased from 
Taconic. C57BL/6, B10.D2-Hc1 H2d H2-T18c/nSnJ (B10.D2), B10.D2-Hc0 
H2d H2-T18c/o2SnJ (C5/), B10.A-H2a, BALB/c, BALB/k, CB6, and 
BALB/c FcRIIb-deficient and both C57BL/6 and BALB/c background 
RAG2-deficient  mice  were  purchased  from  the  Jackson  Laboratory. 
C57BL/6 background C3-deficient (a gift of M. Wills-Karp, CCRF) and 
FcRI- and FcRIII-deficient mice (gifts from J. Ravetch, The Rockefeller 
University, New York, NY) were bred with BALB/c (C3 deficient) and 
B10.D2 (FcRI and FcRIII) background mice to produce C3-deficient, 
FcRI-deficient, FcRIII-deficient, and FcRI/III-deficient mice on an 
H-2d/d background and typed by PCR for the presence of C3, FcRI, and 
FcRIII and by flow cytometry for H-2d and b. Littermates of similar matched 
mixed lineage, but C3, FcRI, and FcRIII sufficient, that were also on a 
H-2d/d background and bred as controls along with B10.D2. BALB/c back-
ground C3aR-, C5L2-, and C5aR-deficient mice (a gift from C. Gerard, 
Harvard University, Cambridge, MA) were used.
H-2 typing. Peripheral blood leukocyte H-2 haplotyping was performed   
by flow cytometry after staining with AF6-88.53 (H-2b specific) conju-
gated to Alexa Fluor 647 and SF1-1.1.10 (H-2d specific) conjugated to 
FITC (BioLegend).
PCR genotyping. FcR-deficient and -sufficient mice were genotyped   
using a protocol and primer sequences supplied by Taconic. C3-sufficient and JEM Vol. 208, No. 12 
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Quantitation of C3 and IgG2a binding to targeted blood cells. Blood 
was collected from an incised tail vein into a heparin-containing tube on ice. 
Erythrocytes were lysed with ammonium chloride lysis solution at 4°C, and 
nucleated cells were washed twice by centrifugation with cold HBSS. Cells 
were stained with biotinylated anti-C3 pAb (ICN Biomedicals Inc./Cappel) 
and anti–mouse IgG2a fluorochrome-labeled mAbs (BD) and then analyzed 
by flow cytometry with a FACSCalibur (BD).
C3 and C5 ELISAs. Blood from tail vein was drawn into K2-EDTA–
containing  tubes  (BD)  on  ice  and  centrifuged  for  separation  of  plasma. 
Plasma was aliquoted and stored at 80oC. Plasma C3 concentration was 
measured according to the manufacturer’s instructions using a mouse C3 
ELISA kit (Immunology Consultants Laboratory). Plasma C5 concentration 
was detected by sandwich ELISA, using rabbit anti–mouse C5 pAb (Cedarlane 
Laboratories) to capture C5, a biotin-labeled preparation of the same Ab to 
detect bound C5 and streptavidin followed by the luminogenic substrate, 
Supersignal (Thermo Fisher Scientific). An ELISA plate reader from Fluo-
roskan Ascent FL was used to measure luminescence.
Plasma transfer. Blood was drawn from the tail veins of genetic background– 
and  gender-matched  mice  into  3.2%  sodium  citrate–containing  tubes   
(1:10 [vol/vol]) on ice and centrifuged at 4oC, and plasma was separated and 
pooled, aliquoted, and stored at 80°C. 400 µl of the pooled plasma was in-
jected i.v. 60 and 30 min before challenge with 34-1-2s or control mAb, 
which were both diluted in 200 µl of the same pooled plasma.
Generation  of  BM  chimeric  mice.  RAG2-deficient  or  -sufficient 
C57BL/6 and BALB/c background male mice were injected i.p. with 50 µl 
anti-asialo GM1 antiserum, (Wako Chemicals USA) and then exposed to 
350 rads of gamma radiation. The next day, the irradiated mice were injected 
i.v. with 15–24 million BM cells from donor C57BL/6 or BALB/c back-
ground RAG2-deficient or CB6 mice. The mice were fed doxycycline-
containing  food  for  2  wk  followed  by  conventional  chow  thereafter. 
Peripheral blood obtained 6 wk after reconstitution was analyzed by flow 
cytometry for percentage of H-2d and H-2b cells.
LPS treatment. Mice were anesthetized with AnaSed and ketamine i.p. and 
then suspended by their incisors in the upright position followed by instillation 
of 2 µg LPS i.t. (Salmonella enterica; Sigma-Aldrich). Mice were allowed to re-
cover and then challenged i.v. 3 d later with 8 (Fig. 6 E) or 125 µg (Fig. 6 D) 
34-1-2s and followed for the development of symptoms of mTRALI.
Statistics. A two-tailed Mann-Whitney t test (Prism; GraphPad Software) 
was used to assess differences between treatment groups. A Pearson correlation 
(PrismA) was used to evaluate the coefficient of determination (r2) of the two 
variables. Linear regression was used to plot the best-fit line with 95% confi-
dence bands. A p-value <0.05 was used as the demarcation of significance.
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